← back to search

Joris van de Haar

The Netherlands Cancer Institute ·
Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Lung Cancer Research Studies, and Cancer Genomics and Diagnostics.
h-index
18
citations
4,034
works
112
NIH funding
primary concept
Biology
email

Recent publications

ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice
Annals of Oncology 2025cited by 42position: middledoi
ESMO Recommendations on clinical reporting of genomic test results for solid cancers
Annals of Oncology 2024cited by 46position: firstdoi
Combining Genomic Biomarkers to Guide Immunotherapy in Non–Small Cell Lung Cancer
Clinical Cancer Research 2024cited by 29position: firstdoi
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma
Scientific Reports 2024cited by 13position: middledoi
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer
Nature Medicine 2023cited by 81position: firstdoi
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
Clinical Cancer Research 2022cited by 85position: middledoi
Caring for patients with cancer in the COVID-19 era
Nature Medicine 2020cited by 342position: firstdoi
Author Correction: Caring for patients with cancer in the COVID-19 era
Nature Medicine 2020cited by 12position: firstdoi
Identifying Epistasis in Cancer Genomes: A Delicate Affair
Cell 2019cited by 106position: firstdoi
MHC-I Genotype Restricts the Oncogenic Mutational Landscape
Cell 2017cited by 367position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Emile E. Voest · Oncode Institute5 papers (2019–2024)Fabrice Barlési · Guangdong Academy of Medical Sciences2 papers (2020–2020)Carlos Caldas · Concern Foundation2 papers (2020–2020)Trey Ideker · UC San Diego Health System2 papers (2017–2019)Jean Charles Soria · Amgen (United States)2 papers (2020–2020)Dirk Jäger · German Cancer Research Center2 papers (2020–2020)Stefan Fröhling · German Cancer Research Center2 papers (2020–2020)Filippo de Braud · National Cancer Institute2 papers (2020–2020)Josep Tabernero · Medical Research Network2 papers (2020–2020)Lodewyk F.A. Wessels · Oncode Institute2 papers (2019–2024)Benjamin Besse · Institut Gustave Roussy2 papers (2020–2020)Ingemar Ernberg · Karolinska Institutet2 papers (2020–2020)Alejandro Piris‐Giménez · Vall d'Hebron Hospital Universitari2 papers (2020–2020)Franco Valenza · Fondazione IRCCS Istituto Nazionale dei Tumori2 papers (2020–2020)Kim Monkhorst · Dutch Cancer Society2 papers (2024–2024)Giovanni Apolone · Università Campus Bio-Medico2 papers (2020–2020)Louisa R. Hoes · The Netherlands Cancer Institute2 papers (2020–2020)Luigi De Petris · Karolinska University Hospital2 papers (2020–2020)Elena Garralda · University College London2 papers (2020–2020)Kenneth B. Seamon · Revolution Medicines (United States)2 papers (2020–2020)